AstraZeneca will pay up to $420M for Moderna's mRNA technology

Moderna Therapeutics granted AstraZeneca five-year exclusive rights to use its messenger RNA technology to develop and market treatments for cancer and other serious diseases. Moderna will receive $240 million upfront and as much as $180 million in milestone fees plus sales royalties. The deal's initial payment is one of the biggest ever in a pharmaceutical licensing agreement that doesn't involve a clinical-stage drug.

View Full Article in:

New York Times (tiered subscription model), The · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC